Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Humacyte, Inc. (HUMA) Institutional Ownership & Insider Trading

162 institutions reported holding Humacyte, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 7 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

HUMAHumacyte, Inc.Follow HUMA — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
121.0M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
6 Nov, in 13 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

162 institutions held 26.4% of the shares. Across filers that reported both quarters, shares held changed +23.8%.

Increased+54New+35Decreased-36Closed-31

Largest moves, shares (millions)

Alyeska Investment Group+6.0MDavidson Kempner Capital…+5.0MAntipodes Partners+4.4MBlackRock-7.5MState Street-2.2MWoodline Partners-1.5M

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters
+4.0Sep 24+6.6Dec 24+18.5Mar 25-3.6Jun 25-11.1Sep 25+9.4Dec 25+2.6Mar 26+14.0Jun 26
QuarterHoldersShares held, MChangeIncreasedNewDecreasedClosed
Jun 2616273+23.8%54353631
Mar 2615759+5.6%53272718
Dec 2514655+20.4%50213614
Sep 2513846-19.5%37114227
Jun 2515557-6.0%69302435
Mar 2516661+44.4%54343527
Dec 2416242+18.6%51323621
Sep 2414136+16.6%53332314

Humacyte, Inc. — questions

Who owns Humacyte, Inc. stock?
162 institutions reported Humacyte, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: VANGUARD CAPITAL MANAGEMENT LLC (3.6%), ANTIPODES PARTNERS Ltd (3.6%), Alyeska Investment Group, L.P. (2.2%).
Are Humacyte, Inc. insiders buying or selling?
7 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Humacyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.